Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
FROM THE WIRE · MANILATIMES.NET
Agreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share.Proposed acquisition brings an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform.Closing anticipated to occur in late December…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAll-cash acquisition of a listed pharma company, implying a premium for Aytu shareholders.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Rosemont will acquire Aytu for $2.70 in cash per share.
- 02Aytu brings an established ADHD portfolio and an emerging major depressive disorder asset.
- 03Closing is anticipated in late December 2026, subject to tender offer conditions.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets